Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cancer Anorexia Market Insight, Epidemiology, and Market Forecast - 2036 Report Reveals Why a ~$500M Market Still Has No Approved Therapy in the US or Europe as Artelo's ART27.13 Nears Phase II Readout

globenewswire.com
ARTL Artelo Biosciences' ART27.13 showed positive interim Phase II results with patients gaining weight, and top-line data is expected soon. This suggests potential for a new therapy in a market with significant unmet needs.

Cancer Anorexia Market Insight, Epidemiology, and Market Forecast - 2036 Report Reveals Why a ~$500M Market Still Has No Approved Therapy in the US or Europe as Artelo's ART27.13 Nears Phase II Readout Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Cancer Anorexia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

Research and Markets has published Cancer Anorexia - Market Insight, Epidemiology, and Market Forecast - 2036, a 200-page report published in July 2026. The report puts the cancer anorexia market across the seven major markets (7MM) at about $500 million in 2025. It provides historical and forecast analysis for 2022-2036 across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Key Facts

A Significant Unmet Need

Cancer anorexia develops frequently in patients with advanced cancers, including:

The 2020 ASCO guidelines recommend no specific drug treatment as standard of care. The only approved therapy for the related condition of cancer cachexia is anamorelin (ADLUMIZ), from Helsinn Healthcare and Ono Pharmaceutical, and it is available only in Japan.

The report also finds that cancer anorexia is significantly underdiagnosed, because routine oncology practice lacks standardised screening protocols and clear diagnostic criteria.

Current Treatment Landscape

Management today is mainly symptomatic. It relies on appetite stimulants such as megestrol acetate, short-term corticosteroids such as dexamethasone, nutritional support, and physical activity. The report notes that these approaches do not address the underlying metabolic and inflammatory drivers of the condition.

Market Drivers

The report identifies three factors driving the market:

Pipeline Analysis

The pipeline remains limited and is driven mainly by smaller biotech companies. ART27.13 from Artelo Biosciences is a once-daily oral dual cannabinoid receptor agonist targeting CB1 and CB2. It was originally developed by AstraZeneca and has been studied in seven clinical trials involving more than 280 participants.

In November 2025, Artelo reported interim Phase II Cancer Appetite Recovery Study (CAReS) results. Patients receiving the top dose gained an average of 6.4% in weight. Artelo expects top-line data in the second half of 2026 or the first half of 2027.

Unmet Needs

The report highlights four gaps in current care:

KOL Insights

Analysts consulted more than 15 key opinion leaders at centres including the Duke Molecular Physiology Institute, Hospital Universitario Fundación Alcorcón, and Nippon Medical School.

Report Scope

The report covers:

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/g16p3w

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.